Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 14/20 | 0.44 |
| ▸ | CTSL | P07711 | 9/20 | 0.44 |
| ▸ | CTSK | P43235 | 6/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3315733 | 0.99 | CTSS (0.43) | CTSSCTSLCTSKCTSBNSD2 | |
| SCHEMBL4432656 | 0.82 | CTSS (0.40) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3319971 | 0.82 | CTSS (0.40) | CTSSCTSLCTSKCTSBNSD2 | |
| SCHEMBL3318584 | 0.81 | CTSS (0.38) | CTSSCTSLCTSKCTSBNSD2 | |
| SCHEMBL4429647 | 0.81 | CTSS (0.38) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3315752 | 0.80 | CTSL (0.45) | CTSSCTSLCTSKCTSBCDK1 | |
| SCHEMBL3320171 | 0.80 | CTSS (0.36) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3318590 | 0.79 | CTSL (0.48) | CTSSCTSLCTSKCTSB | |
| Trifluoroacetic Acid SCHEMBL3320169 | 0.79 | CTSS (0.37) | CTSSCTSLCTSKCTSB | |
| SCHEMBL3318200 | 0.79 | CTSL (0.43) | CTSSCTSLCTSKCTSBCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| EP-2118106-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| EP-2028182-A1 | Cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-02-25 | — | — | EP | disclosed |
| WO-2008107368-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | CPN1, SERPINB1, PNP | CTSS 37/4885CTSL 31/4885CTSK 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.